ICU Medical Inc: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Nov 6, 2020 and accepted by EDGAR at Nov 6, 2020, 15:27 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-07-01 to 2020-09-30 | $318.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2020-01-01 to 2020-09-30 | $950.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-07-01 to 2020-09-30 | $204.6m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2020-01-01 to 2020-09-30 | $608.9m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2020-07-01 to 2020-09-30 | $113.9m | us-gaap:GrossProfit |
| Gross profit | 9 months2020-01-01 to 2020-09-30 | $341.6m | us-gaap:GrossProfit |
| Research and development | 3 months2020-07-01 to 2020-09-30 | $10.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-01-01 to 2020-09-30 | $31.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2020-07-01 to 2020-09-30 | $70.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2020-01-01 to 2020-09-30 | $210.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | $25.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | $71.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-07-01 to 2020-09-30 | $616.0k | us-gaap:InterestExpense |
| Interest expense | 9 months2020-01-01 to 2020-09-30 | $1.6m | us-gaap:InterestExpense |
| Income tax | 3 months2020-07-01 to 2020-09-30 | $1.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2020-01-01 to 2020-09-30 | $6.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-07-01 to 2020-09-30 | $25.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | $60.7m | us-gaap:ProfitLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | $1.16 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | $2.82 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-07-01 to 2020-09-30 | $1.19 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2020-01-01 to 2020-09-30 | $2.91 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-07-01 to 2020-09-30 | 21,556,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2020-01-01 to 2020-09-30 | 21,561,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | $144.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-01-01 to 2020-09-30 | $62.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-09-30 | $351.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $900.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $1.73bn | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $185.4m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2020-09-30 | $1.45bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000883984-20-000038. Last ingested by Listed: Nov 14, 2026, 20:54 ET. Listed shows no prices and gives no investment advice.